OcuNex
Alternative Names: Ono 9001Latest Information Update: 15 Oct 1999
At a glance
- Originator Telios Pharmaceuticals
- Developer Ono Pharmaceutical; Telios Pharmaceuticals
- Class Eye disorder therapies; Peptides
- Mechanism of Action Peptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 15 Oct 1999 No-Development-Reported for Corneal ulcer in USA (Ophthalmic)
- 12 Oct 1996 Discontinued-II for Corneal ulcer in Japan (Ophthalmic)
- 12 Oct 1996 Discontinued-II for Corneal ulcer in South Korea (Ophthalmic)